Fosamax Litigation Continues

Will the U.S. Supreme Court find Merck liable for failing to provide adequate warnings about Fosamax?Fosamax is a prescription drug manufactured by mega-company Merck.  It was created to help treat osteoporosis and other diseases that cause bone...

Read More

Heart arrhythmiaExcessive bleedingCoughing up bloodBlood pressure changesNosebleedsGastrointestinal bleedingRectal bleedingBrain hemorrhagingDeathThe immense dangers of Xarelto are largely linked to its lack of an antidote. When Xarelto was initially released in 2011, it did not have an antidote that could reverse internal or external bleeding that could occur due to surgery, an accident, or a side effect of the drug. Warfarin, on the other hand, has a reversing agent that can quickly stop the effects of the drug to stop bleeding fast. According to several lawsuits and safety officials, the makers of Xarelto did not adequately warn physicians or patients as to the lack of an antidote and the related serious risks of ongoing bleeding. Anyone who has suffered an injury due to Xarelto may be eligible to seek compensation from the makers of this dangerous drug. Injuries linked to Xarelto can inflict financial hardships on patients. Xarelto victims may be able to seek compensation for their medical expenses, lost wages, pain and suffering, and other ongoing disabilities stemming from the drug. Contact a defective drug attorney for an analysis of your legal rights and overview of your necessary next steps.

What injuries have been linked to Xarelto? Xarelto (rivaroxaban) is a drug released by Bayer Healthcare in tandem with Janssen Pharmaceuticals to thin the blood. Xarelto is prescribed to patients at risk of stroke or those with atrial fibrillation in...

Read More

Heartburn Drugs May Pose Health Risks

Can I file a lawsuit against a pharmaceutical company if I am injured by a medication?A recent clinical study by the Houston Methodist Research Institute indicates that a class of heartburn drugs, proton pump inhibitors or PPIs, put users at increase...

Read More